Human immunoglobulin market to surge by $9.7b through 2028

One key driver is the rising demand for treatments in hospitals and homecare settings.

The global human immunoglobulin market is projected to rise by $9.7b through 2028 at an estimated compound annual growth rate (CAGR) of 10.11%, according to Technavio.

The sector’s expansion is attributed to an increase in plasma donation and a rising demand for treatments for associated conditions.

“Hospitals use Intravenous Immunoglobulin (IVIG) for therapeutic applications in patients with Primary Immunodeficiency (PI), Guillain-Barre Syndrome, and other immunology-related disorders,” the report said.

Furthermore, Subcutaneous Immunoglobulin (SCIg) is gaining traction in homecare settings, particularly for the geriatric population and individuals with lifestyle-related illnesses.

Meanwhile, the market is witnessing a trend towards the rise of research and development initiatives.

Key industry players are also expanding their product offerings and enhancing existing therapies to meet the increasing demand for immunoglobulin treatments.

Additionally, healthcare initiatives, plasma collection and fractionation, along with immunisation programs, are contributing to the market's expansion.